Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902815 | 1.00 | PPARG (0.77) | PPARGCYP3A4RXRAFFAR1MEN1 | |
| SCHEMBL8308611 | 0.87 | PPARG (0.76) | PPARGCYP3A4RXRAFFAR1RARG | |
| SCHEMBL8308613 | 0.87 | PPARG (0.76) | PPARGCYP3A4RXRAFFAR1RARG | |
| SCHEMBL6898697 | 0.87 | PPARG (1.00) | PPARGCYP3A4RXRAFFAR1MEN1 | |
| SCHEMBL6898699 | 0.87 | PPARG (1.00) | PPARGCYP3A4RXRAFFAR1MEN1 | |
| SCHEMBL8309658 | 0.86 | PPARG (0.76) | PPARGCYP3A4FFAR1MEN1ALDH1A1 | |
| SCHEMBL8309657 | 0.86 | PPARG (0.76) | PPARGCYP3A4FFAR1MEN1ALDH1A1 | |
| SCHEMBL8305416 | 0.86 | PPARG (0.76) | PPARGCYP3A4RXRAFFAR1MEN1 | |
| SCHEMBL8305406 | 0.86 | PPARG (0.76) | PPARGCYP3A4RXRAFFAR1MEN1 | |
| SCHEMBL6899309 | 0.85 | PPARG (0.81) | PPARGCYP3A4FFAR1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | claimed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | claimed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | claimed |
| EP-0919232-B1 | Composition for use in the treatment and prevention of hyperuricemia | SANKYO CO (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0953355-A1 | REMEDY FOR AUTOIMMUNE DISEASES | Sankyo Company, Limited (JP) | 1999-11-03 | — | — | EP | disclosed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | disclosed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |